HER2 Alterations in Non-Small Cell Lung Cancer

A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.

EP. 1: Biomarker Testing in NSCLC: Clinical Scenario

September 12th 2022

A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.

EP. 2: Approaches to Biomarker Testing in NSCLC

September 12th 2022

Timothy Craig Allen, MD, JD, FCAP, explains how he approaches biomarker testing in NSCLC and what testing he would have ordered in the presented scenario.

EP. 3: Liquid vs Solid Tumor Biopsies in NSCLC

September 20th 2022

Mark A. Socinski, MD, debates the merits of liquid versus tissue tumor biopsies in NSCLC biomarker testing.

EP. 4: HER2 Alterations in NSCLC: Clinical Scenario

September 20th 2022

Dr Solange Peters shares the molecular testing results for the patient in the presented clinical scenario.

EP. 5: The Role of HER2 Alterations in NSCLC

September 29th 2022

Drs Allen and Socinski discussion the role of HER2 alterations in NSCLC and how it differs from breast cancer.

EP. 6: Testing Patients with NSCLC for HER2 Mutations

September 29th 2022

Anil Vachani, MD, MS, explains whether he orders biomarker testing for all patients with HER2-mutated NSCLC.

EP. 7: Current Treatment Options in NSCLC

October 4th 2022

Dr Mark A Socinski reviews the currently available treatment options for NSCLC, including targeted therapies.

EP. 8: Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC

October 4th 2022

Solange Peters, MD, PhD, presents the case of a 72-year-old man with HER2-amplified NSCLC and starts a discussion on the recommended treatment plans.

EP. 9: HER2-Targeted Therapies in NSCLC

October 10th 2022

Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.

EP. 10: Major Adverse Events of Anti-HER2 Therapies

October 10th 2022

Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.

EP. 11: Unmet Needs in NSCLC Therapy

October 17th 2022

Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.

EP. 12: Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC

October 17th 2022

The panel discusses the challenges of treatment and unmet needs of HER2-mutated or amplified NSCLC.

EP. 13: Novel HER2-Targeted Therapies for NSCLC

October 17th 2022

Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.